4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-ethoxy-7-(4-hydroxybut-1-ynyl)-3-quinolinecarbonitrile | 885483-00-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-ethoxy-7-(4-hydroxybut-1-ynyl)-3-quinolinecarbonitrile
• 英文别名: 4-(2,4-dichloro-5-methoxyanilino)-6-ethoxy-7-(4-hydroxybut-1-ynyl)quinoline-3-carbonitrile
• CAS: 885483-00-1
• 化学式: C₂₃H₁₉Cl₂N₃O₃
• 分子量: 456.328
• InChiKey: LZMAMVQUHIUNBU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.5
• 重原子数：
  31
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  87.4
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-ethoxy-7-(4-hydroxybut-1-ynyl)-3-quinolinecarbonitrile 在 三乙胺 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 1.25h， 生成 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-ethoxy-7-[4-(4-methylpiperazin-1-yl)but-1-ynyl]-3-quinolinecarbonitrile
  参考文献：
  名称：

  Inhibition of Src kinase activity by 7-ethynyl-4-phenylamino-3-quinolinecarbonitriles: Identification of SKS-927

  摘要：

  Of a series of 7-ethynyl-3-quinolinecarbonitriles, the most potent Src inhibitory activity was observed with 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[4-(4-methylpiperazin-1-yl)but-1-ynyl]-3-quinolinecarbonitrile (SKS-927). Variation of the solubilizing amine tail or removal of the methoxy group from either C-6 of the quinoline core or C-5 of the aniline headpiece led to reduced activity. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.11.077
• 作为产物：
  描述：

  4-乙氧基-3-碘-苯胺 在 copper(l) iodide 、 四(三苯基膦)钯 、 三乙胺 、 三氯氧磷 作用下， 以 1,4-二氧六环 、 异丙醇 为溶剂， 反应 3.0h， 生成 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-ethoxy-7-(4-hydroxybut-1-ynyl)-3-quinolinecarbonitrile
  参考文献：
  名称：

  Inhibition of Src kinase activity by 7-ethynyl-4-phenylamino-3-quinolinecarbonitriles: Identification of SKS-927

  摘要：

  Of a series of 7-ethynyl-3-quinolinecarbonitriles, the most potent Src inhibitory activity was observed with 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[4-(4-methylpiperazin-1-yl)but-1-ynyl]-3-quinolinecarbonitrile (SKS-927). Variation of the solubilizing amine tail or removal of the methoxy group from either C-6 of the quinoline core or C-5 of the aniline headpiece led to reduced activity. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.11.077

文献信息

• 4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-alkoxy-7-ethynyl-3-quinolinecarbonitriles for the treatment of ischemic injury
  申请人：Boschelli Harris Diane

  公开号：US20060116375A1

  公开（公告）日：2006-06-01

  Compounds of the formula: wherein: R is methyl or ethyl; R′ and R″ are independently alkyl of 1 to 3 carbon atoms, or R′ and R″, taken together with the nitrogen to which they are attached, can form a 5 or 6 membered saturated ring which may optionally contain an additional heteroatom selected from NR′″, O or S(O) n ; n is 0-2; and R′″ is hydrogen or alkyl of 1 to 3 carbon atoms, and pharmaceutically acceptable salts thereof, and their use for inhibiting vascular permeability caused by disease, injury or other trauma.

  该化合物的化学式为：其中：R为甲基或乙基；R′和R″分别是1至3个碳原子的烷基，或者R′和R″与它们所连接的氮原子一起形成一个5或6个成员的饱和环，该环可以选择性地包含一个来自NR′″、O或S（O）n的额外杂原子；n为0-2；R′″为氢或1至3个碳原子的烷基，以及其药学上可接受的盐，并且它们可用于抑制由疾病、损伤或其他创伤引起的血管通透性。
• WO2006/47262
  申请人：——

  公开号：——

  公开（公告）日：——
• 4 [(2,4-DICHLORO-5-METHOXYPHENYL)AMINO]-6-ALKOXY-7-ETHYNYL-3-QUINOLINECARBONITRILES FOR THE TREATMENT OF ISCHEMIC INJURY
  申请人：Wyeth

  公开号：EP1802581B1

  公开（公告）日：2008-04-02
• Inhibition of Src kinase activity by 7-ethynyl-4-phenylamino-3-quinolinecarbonitriles: Identification of SKS-927
  作者：Diane H. Boschelli、Ana Carolina Barrios Sosa、Jennifer M. Golas、Frank Boschelli

  DOI：10.1016/j.bmcl.2006.11.077

  日期：2007.3

  Of a series of 7-ethynyl-3-quinolinecarbonitriles, the most potent Src inhibitory activity was observed with 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[4-(4-methylpiperazin-1-yl)but-1-ynyl]-3-quinolinecarbonitrile (SKS-927). Variation of the solubilizing amine tail or removal of the methoxy group from either C-6 of the quinoline core or C-5 of the aniline headpiece led to reduced activity. (c) 2006 Elsevier Ltd. All rights reserved.